Bayer to manufacture CureVac COVID-19 vaccine
Alongside the German government and Franz-Werner Haas, Chief Executive Officer of CureVac N.V., Stefan Oelrich, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division announced plans for the pharmaceutical company to manufacture the CureVac mRNA COVID-19 vaccine in Germany.
“Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variants of the SARS-CoV-2 virus. This includes the need to expand production capacity as well as related manufacturing expertise in Germany. We at Bayer will contribute even further by making more vaccines available to help fight the pandemic,” commented Oelrich.
Bayer will be providing an additional 160 million doses of CureVac’s vaccine in 2022 to further expand their supply network and overall capacity by using the manufacturing network of Bayer. “First commercial product from this expansion may already be available towards the end of this year,” added Oelrich.
Bayer and CureVac’s partnership
The latest plans announced by Bayer furthers the pharmaceutical company’s current support it is providing CureVac which include, the development, supply and key territory operations of CureVac’s vaccine candidate.
Bayer provides CureVac with “its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain management as well as support with country operations within the European Union and selected additional markets,” said Oelrich.
Since forming its alliance with CureVac in early 2021, Bayer has been striving to further contribute to CureVac’s operations by providing end-to-end manufacturing.
“Although we have not previously produced vaccines, we hold strong expertise in the development of biotech products [...] I am glad to report today that we have the necessary skills and capabilities at Bayer to manufacture CureVac’s mRNA-based vaccine,” stated Oelrich.
Vuram launches automated app to track COVID-19 supplies
A new app that tracks COVID-19 supplies in real time time has launched.
Built by hyper-automation services company Vuram, Trackable can monitor the progress of vaccines, oxygen cylinders, PPE, and masks as they move through the supply chain.
The app's features include street view to facilitate coordination between drivers, and trained facial recognition software powered by Microsoft Azure to ensure goods are only handled by authorised personnel.
Other functions include:
* Demand management for inventories, to prioritise deliveries using automation
* Demand analysis to predict sales trends based on stock levels
* Offline multilingual feature for drivers
* A dashboard to see the status and location of drivers
* Insights on how products are performing in real-time
The team at Vuram built Trackable as part of the Appian World 2021 Online Hackathon, where participants can take their ideas for innovative software and create a custom app. The tracking app went on to win the contest.
“Custom component building is at the heart of this application, and we focussed on making them more creative to provide an improved user experience" said Santosh Kumar, co-developer of Trackable.
"We are happy that we have managed to make it to the top in just a month. On behalf of Vuram, I thank the Appian Hackathon team for their efforts in conducting the event, and my hearty congratulations to all the winners."